VaxInnate Corporation Begins Phase I Clinical Trial To Evaluate Quadrivalent Vaccine For Prevention Of Seasonal Flu

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation today announced that enrollment has commenced in a Phase 1 clinical trial to evaluate VAX2012Q, a recombinant quadrivalent vaccine in development for the prevention of seasonal influenza. VaxInnate is a biotechnology firm pioneering a breakthrough technology platform for the development of novel vaccines.

Help employers find you! Check out all the jobs and post your resume.

Back to news